GT Biopharma, Inc. (GTBP) Aandelenanalyse

Bedrijfsoverzicht

GT Biopharma, Inc. is a clinical stage biopharmaceutical company dedicated to the development and commercialization of immuno-oncology products derived from its Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) platforms. The company currently focuses on advancing GTB-3650, which is in phase 1 of development, representing a significant early-stage asset within the healthcare sector. Operating specifically within the biotechnology industry, the firm leverages these proprietary platforms to create innovative therapeutic solutions targeting cancer treatments. The company's scale is defined by a market capitalization of $11.64M and an employee count of 1, with annual revenue figures not currently available for the trailing twelve months. These valuation metrics indicate that the company is a micro-cap entity with a very small market presence, suggesting that its primary value proposition lies in the potential future commercialization of its pipeline rather than current operational scale or profitability.

Financiële gezondheid

The company reports a net income of $-34,449,000 for the trailing twelve months, while revenue and EBITDA figures are not available for the reported period. The substantial gap between the negligible revenue data and the significant net loss reveals a cost structure heavily weighted toward research, development, and operational expenses typical of a clinical stage biotechnology firm. Free cash flow stands at $-12,008,125, indicating that the company is consuming cash to fund its operations and product development efforts rather than generating surplus liquidity. Despite the negative cash flow, the company maintains a cash balance of $6.81M and holds no debt, which provides a specific runway for operations but does not offer financial flexibility through leverage. All three margin metrics—gross margin, operating margin, and profit margin—are reported at 0.0%, which is standard for biotechnology companies in early clinical phases where revenue has not yet scaled to cover variable and fixed costs effectively. The balance sheet appears conservative regarding leverage since total debt is $0, although the debt-to-equity ratio is not available due to the lack of equity data. Short-term liquidity is supported by a current ratio of 3.50, suggesting the company possesses sufficient current assets to cover its short-term liabilities more than three times over. Return on Equity is reported at -1377.4% and Return on Assets at -125.9%, metrics that reflect the intense capital expenditure required to bring immuno-oncology products to market before positive returns can be realized.

Waarderingsbeoordeling

The trailing P/E ratio is not available, while the forward P/E is listed as -0.03, implying that the market prices the stock based on future earnings expectations that are currently negative or undefined due to the company's stage of development. The price-to-book ratio is 1.63, indicating that the market values the company at 1.63 times its book value, which may reflect an expectation of significant intangible assets or future patent value not fully captured on the balance sheet. The price-to-sales ratio and EV/EBITDA are both not available, preventing a traditional revenue or earnings-based valuation comparison with established peers. The stock's trading range over the last year spans from a 52-week low of $0.36 to a 52-week high of $3.85, illustrating a wide volatility band common for small-cap biotech stocks. The beta value is 1.20, which signifies that the stock is expected to be 20% more volatile than the broader market, amplifying price swings in response to sector-specific news or general market movements.

Growth & Income

Revenue growth and earnings growth rates are both not available for the year-over-year comparison, as the company has not yet generated significant recurring revenue streams to calculate these percentages. Since the company is not a dividend payer, there is no dividend yield or payout ratio to analyze, meaning all financial resources are theoretically directed toward reinvesting earnings into research and growth initiatives rather than shareholder distributions. The overall growth and income profile is characterized by a lack of current financial returns, with the company relying entirely on the successful advancement of its clinical pipeline to generate future value. This absence of current income and growth metrics underscores the high-risk, high-reward nature of investing in clinical stage biopharmaceutical firms where value creation is contingent on future regulatory approvals and commercial success.